Loading...
StocksRunner logo
 
 
Allogene Therapeutic
5.86
-0.43%
 
ALLO Allogene Therapeutics
Last Price
Change
5.86
 
-0.43%
 
 
 

 
Sentiment
 
  Login to display
 
 

5.32

5.61

7.72

12.28

 
 
1m
3m
6m
1y
 

Summary

  Login to display Allogene Therapeutics (ALLO) recommendation from the last 90 days from financial news and social media.
 

Strengths

Rewards

 Upgraded on attractively valued

Rewards

 Outperform the market

Rewards

 Earnings are forecast to grow

 

Risk Analysis

Risk Analysis

 Enter oversold territory

 
 

Risk Level

 
StocksRunner
 

Allogene Therapeutics (ALLO) has High Risk Level

Click here to check what is your level of risk

 

Analysts Opinion

Click on the category for more information
 
 

Earnings

×
 

Earnings

2.00
 

StocksRunner

 Below analyst estimate

StocksRunner

 Loss widens YoY

 
 

Rating

×
 

Rating

4.60
 

StocksRunner

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

2.00
 

StocksRunner

 Enter oversold territory

 

Activity

×
 

Activity

4.00
 
 

Future

×
 

Future

4.33
 

StocksRunner

 Outperform the market

StocksRunner

 Earnings are forecast to grow

 
 

Analysts Opinion

Analysts opinion is positive and also has improved from the past 3 months

 

Street Consensus

Buy
Opinion
Trend
Score
Potential
Score
 
78%
80%
0%
100%
 
On Track
On Track
On Track
 

Street Opinion 

Street view is extremely ish and have positive views on the near-term outlook

 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
Positive vs Negative
 
78%
17%
Positive
Negative
14 out of 18
events present
3 out of 18
events present
 

 
Events Calendar
Click for more information
 
May
S
M
T
W
T
F
S
June
S
M
T
W
T
F
S
 
Highlights
Last
Modify
Closing
Price
%
Change

 
Buy Rating
This Week
5.62
+0.09%
 
Buy Rating
1 Week Ago
5.53
+1.10%
 
Buy Rating
2 Month Ago
6.62
+2.56%
 
Weak Earnings
2 Month Ago
6.45
+12.76%
 
Weak Earnings
2 Month Ago
5.71
+6.73%
 
Top Headlines

jmp securities reiterates allogene therapeutics (allo) market outperform recommendation. fintel reports that on june 5 2023 jmp securities reiterated coverage of allogene therapeutics (nasdaq:allo) with a market outperform rec

Mon Jun 5, 2023

Potential

ef hutton reiterates allogene therapeutics (allo) buy recommendation. fintel reports that on june 5 2023 ef hutton reiterated coverage of allogene therapeutics (nasdaq:allo) with a buy recommendation.

Mon Jun 5, 2023

Rating

ef hutton reiterates allogene therapeutics (allo) buy recommendation. fintel reports that on may 26 2023 ef hutton reiterated coverage of allogene therapeutics (nasdaq:allo) with a buy recommendation.

Fri May 26, 2023

Rating

wall street analysts think allogene therapeutics (allo) could surge 184.59%: read this before placing a bet. allogene therapeutics (allo) closed the last trading session at $6.23 gaining 34% over the past four weeks but there could be

Wed May 10, 2023

Potential

hc wainwright & co. reiterates allogene therapeutics (allo) buy recommendation. fintel reports that on may 5 2023 hc wainwright &. co. reiterated coverage of allogene therapeutics (nasdaq:allo) with a buy recommendation.

Fri May 5, 2023

Rating

jmp securities maintains allogene therapeutics (allo) outperform recommendation. fintel reports that on may 5 2023 jmp securities maintained coverage of allogene therapeutics (nasdaq:allo) with a outperform recommendation.

Fri May 5, 2023

Potential

stifel maintains allogene therapeutics (allo) hold recommendation. fintel reports that on may 4 2023 stifel maintained coverage of allogene therapeutics (nasdaq:allo) with a hold recommendation.

Fri May 5, 2023

Rating

rbc capital reiterates allogene therapeutics (allo) outperform recommendation. fintel reports that on may 4 2023 rbc capital reiterated coverage of allogene therapeutics (nasdaq:allo) with a outperform recommendation.

Fri May 5, 2023

Potential

allogenes (allo) q1 loss wider than expected sales miss. allogene therapeutics inc. allo incurred a loss of 68 cents per share in first-quarter 2023 wider than the zacks consensus estimate and our model estimate of a loss of 63 cents a

Thu May 4, 2023

Earnings

allogene therapeutics (allo) reports q1 loss misses revenue estimates. allogene therapeutics (allo) came out with a quarterly loss of $0.68 per share versus the zacks consensus estimate of a loss of $0.63. this compares to loss of $0.5

Wed May 3, 2023

Earnings

allogene therapeutics gaap eps of -$0.68 misses by $0.06 revenue of $0.05m beats by $0.04m.

Wed May 3, 2023

Earnings

wall street analysts believe allogene therapeutics (allo) could rally 278.19%: heres is how to trade. shares of allogene therapeutics (allo) have gained 7.8% over the past four weeks to close the last trading session at $5.41 but there

Mon Apr 24, 2023

Potential
Potential

hc wainwright & co. reiterates allogene therapeutics (allo) buy recommendation. fintel reports that on april 20 2023 hc wainwright &. co. reiterated coverage of allogene therapeutics (nasdaq:allo) with a buy recommendation.

Fri Apr 21, 2023

Rating

heres why you should add allogene (allo) stock to your portfolio. allogene therapeutics (allo) is a san diego ca-based biopharmaceutical company developing and commercializing genetically engineered allogenic t-cell therapies for cance

Wed Apr 19, 2023

Activity
Potential

jmp securities reiterates allogene therapeutics (allo) market outperform recommendation. fintel reports that on april 18 2023 jmp securities reiterated coverage of allo

Wed Apr 19, 2023

Potential

 
 
 
StocksRunner

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our daily ALLO alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

 
Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

 
Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
About Us

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
StocksRunner

StocksRunner

Get the pulse of the market

 
StocksRunner

ALLO Allogene Therapeutics

Last Price
5.86
Change
-0.43%
 

Summary

  Login to display Allogene Therapeutics (ALLO) recommendation from the last 90 days from financial news and social media.

 
 
5.32
5.61
7.72
12.28
 
 
1m
3m
6m
1y
 
Sentiment
 

  Login to display

Strengths

Rewards

 Upgraded on attractively valued

Rewards

 Outperform the market

Rewards

 Earnings are forecast to grow

Risk Analysis

Risk Analysis

 Enter oversold territory

 
 
 
 
Street Consensus
 
Buy
Opinion
Trend
Score
Potential
Score
 
80%
0%
100%
On Track
On Track
On Track
 
78%
17%
Positive
Negative
14 out of 18
events present
3 out of 18
events present
 

Street Opinion

Street view is extremely ish and have positive views on the near-term outlook

 
 
Analysts Opinion
Hover the category for more information
 
 

Earnings

×
 

Earnings

2.00
 

StocksRunner

 Below analyst estimate

StocksRunner

 Loss widens YoY

 
 

Rating

×
 

Rating

4.60
 

StocksRunner

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

2.00
 

StocksRunner

 Enter oversold territory

 

Activity

×
 

Activity

4.00
 
 

Future

×
 

Future

4.33
 

StocksRunner

 Outperform the market

StocksRunner

 Earnings are forecast to grow

 
 

Analysts Opinion

Analysts opinion is positive and also has improved from the past 3 months

 
 
 
 
 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
 
Risk Level
 
StocksRunner
 

Allogene Therapeutics (ALLO) has High Risk Level.  Click here to check what is your level of risk

 
 
 

Events Calendar

Hover for information

 
May
 
S
M
T
W
T
F
S
 
June
 
S
M
T
W
T
F
S
 
 
 
 
Highlights
Last
Modify
Closing
Price
%
Change

 
Buy Rating
This Week
5.62
+0.09%
 
Buy Rating
1 Week Ago
5.53
+1.10%
 
Buy Rating
2 Month Ago
6.62
+2.56%
 
Weak Earnings
2 Month Ago
6.45
+12.76%
 
Weak Earnings
2 Month Ago
5.71
+6.73%
 
 
 
StocksRunner

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our daily ALLO Alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
 
 

Top Headlines